DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge

Modified vaccinia Ankara (MVA) is being tested in humans as an alternative to the current smallpox vaccine Dryvax. Here, we compare the magnitude and longevity of protective immune responses elicited by a DNA/MVA HIV-1 vaccine with those elicited by Dryvax using a monkeypox virus/macaque model. The...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Nigam, Pragati, Earl, Patricia L., Americo, Jeffrey L., Sharma, Sunita, Wyatt, Linda S., Edghill-Spano, Yvette, Chennareddi, Lakshmi S., Silvera, Peter, Moss, Bernard, Robinson, Harriet L., Amara, Rama Rao
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier Inc. 2007
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2072046/
https://ncbi.nlm.nih.gov/pubmed/17507071
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.virol.2007.04.010
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items